eik1001
eik1001: developed by 1 company · 3 clinical trials tracked.
eik1001 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could eik1001 → EIKN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Eikon Therapeutics Inc. (EIKN) NSCLC; Advanced Melanoma; Non Small Cell Lung Cancer (Squamo… | Phase 2 |
Clinical Trials (3)
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
Primary endpoint: Progression-free survival (PFS)
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)
Primary endpoint: Progression Free Survival (PFS)
A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer
Primary endpoint: Percentage of participants with safety event during treatment
Frequently asked questions
Who is developing eik1001?
eik1001 is being developed by Eikon Therapeutics Inc..
How many clinical trials involve eik1001?
BioSniper tracks 3 clinical trials involving eik1001.